Genomic technology company Biofidelity on Tuesday announced that it is developing a low-cost, rapid assay for single-molecule detection of multiple gene fusions from RNA to detect non-small cell lung cancer (NSCLC).
The assay, which leverages the firm's Allele-Specific PYrophosphorolysis REaction (ASPYRE) technology, analyzes DNA and RNA concurrently from a single patient sample, the company said, adding that the assay can return results within two days.
Biofidelity researchers recently described the technology in a study in BMC Medical Genomics.
The technology "fits into the underserved space between NGS and PCR testing, enabling fast clinical decision-making through simple, precise, and targeted identification of panels of genomic biomarkers,” Dr. Barnaby Balmforth, paper coauthor and the cofounder and CEO of Biofidelity, said in a statement.
